Go to the list of all blogs
Serhii Bondarenko's Avatar
published in Blogs
Aug 11, 2026
Ferrari (RACE) Shares Climb +8% on Strong Q2 Earnings and Raised Guidance

Ferrari (RACE) Shares Climb +8% on Strong Q2 Earnings and Raised Guidance

Key Takeaways

  • Ferrari shares have climbed approximately 8% over the past 30 days, driven by robust Q2 2026 earnings that exceeded expectations and an upward revision to full-year guidance.
  • The company reported Q2 net revenues of €1.94 billion, up 8% year-over-year, with adjusted EBITDA of €755 million and an EBITDA margin of 39%.
  • Ferrari raised its FY2026 outlook, now projecting at least €9.68 in adjusted diluted EPS and approximately €7.6 billion in revenue, reflecting strong personalization trends and a more favorable FX environment.
  • The order book extends through the entirety of 2027, with high-demand models including the 296 Speciale and Dodici Cilindri families already sold out for their production runs.
  • Wall Street maintains a broadly constructive stance, with a consensus "Moderate Buy" rating and an average 12-month price target above $450.

Ferrari's Recent Stock Performance

Ferrari N.V. shares closed at $406.77 on August 10, 2026, capping a month of steady recovery that saw the stock gain roughly 8% from mid-July levels near $376. The luxury automaker has outperformed broader consumer discretionary benchmarks during this stretch, buoyed by a well-received earnings report and sustained investor confidence in its pricing power. Trading volumes surged around the late-July earnings release, with the stock briefly touching $412.26 before settling into a consolidation range. The stock remains approximately 20% below its 52-week high near $505, reflecting a lingering valuation reset that multiple analysts have characterized as an opportunity rather than a fundamental concern.

Ferrari's Business Model and Competitive Position

Ferrari N.V., headquartered in Maranello, Italy, is one of the world's most recognizable luxury automotive brands. The company designs, engineers, and manufactures high-performance sports cars that command average selling prices well above €500,000. Unlike mass-market automakers, Ferrari deliberately constrains production volumes to preserve exclusivity — shipping just 13,640 units in 2025. The business generates approximately 84% of its revenue from car and spare parts sales, with the remainder derived from sponsorship agreements, brand licensing, and Formula 1 commercial activities. Ferrari's competitive moat rests on a combination of iconic brand equity, a multi-year order backlog, exceptional pricing authority, and a client base dominated by repeat buyers. The company's strategy of layering limited-edition hypercars (such as the F80) and high-margin personalization programs atop its core range has consistently produced industry-leading margins — the EBIT margin reached 31.2% in Q2 2026. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Recent Developments Supporting RACE

The most significant catalyst over the past 30 days was Ferrari's Q2 2026 earnings release on July 30. The company posted net revenues of €1.94 billion (up 8% year-over-year, or 11% at constant currency) and adjusted diluted EPS of €2.62, surpassing analyst consensus estimates. Perhaps more importantly, management raised full-year guidance across nearly every key metric: revenue guidance climbed to approximately €7.6 billion from €7.5 billion, adjusted EBITDA to at least €2.97 billion from €2.93 billion, and adjusted diluted EPS to at least €9.68 from €9.45. CEO Benedetto Vigna attributed the upgraded outlook to stronger-than-expected personalization adoption, which now accounts for over 20% of car and spare parts revenue. Analysts responded favorably — Evercore ISI raised its price target to $485, UBS reiterated its Buy rating with a $490 target, and Morgan Stanley maintained its Overweight stance at $439. On the product front, the company unveiled the 12Cilindri Manuale in Q3, adding a gated-manual variant that has generated significant enthusiast interest. The Ferrari Luce, the brand's first fully electric vehicle unveiled in May, has reportedly reached its 2026 sales target within two months, though some market observers remain cautious about long-term EV demand within Ferrari's traditional client base.

2026 Outlook and Key Factors to Monitor

Looking ahead through the remainder of 2026, several factors will shape Ferrari's investment narrative. The company's next earnings report, estimated for early November, will be closely scrutinized for confirmation that personalization momentum and product mix strength are sustainable into the second half. Currency exposure remains a wildcard — CFO Antonio Picca Piccon noted on the Q2 call that only about 8% of 2027 FX exposure is hedged, leaving results vulnerable to USD/EUR fluctuations. The gradual ramp-up of Luce deliveries beginning in Q4 2026 represents both an opportunity and an overhang; successful execution could expand Ferrari's addressable market, while any misstep might pressure the stock's premium valuation. Analysts will also monitor the pace of D&A normalization as the model changeover cycle progresses, which could compress margins in H2. On the competitive front, Ferrari's deliberate volume restraint and scarcity-driven strategy continue to differentiate it from peers such as Tesla (TSLA) and BMW (BMWYY), though the broader luxury auto segment faces ongoing tariff uncertainty. With an order book extending through 2027 and a consensus analyst price target implying double-digit upside, Ferrari enters the second half of 2026 with considerable operational momentum, even as macroeconomic crosscurrents warrant continued vigilance.

Integrating Tickeron’s AI Tools Into My Process

In my view, AI-driven resources add useful context when evaluating names like Ferrari. I regularly review Tickeron’s Trending AI Robots to see how automated strategies are performing across sectors, including luxury autos. The platform highlights top bots with transparent metrics on win rates and trade history, helping me cross-check my own analysis without replacing it.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: RACE

Contributor

Serhii Bondarenko is an AI-focused trading strategist and financial markets analyst specializing in the development and application of AI trading bots and autonomous trading agents. His work combines technical analysis, fundamental analysis, and quantitative research to identify market patterns, forecast price movements, and analyze liquidity, volatility, and correlations across global stock markets. Serhii actively publishes market insights, forecasts, and trading frameworks on platforms such as Investing.com and Finextra, with a strong focus on AI-driven decision-making and next-generation algorithmic trading. His research aims to bridge the gap between traditional trading methodologies and advanced artificial intelligence, helping traders and investors navigate complex and rapidly evolving market conditions.


RACE's RSI Indicator slumps into oversold zone

The RSI Indicator for RACE moved into overbought territory on October 05, 2026. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +1.74% 3-day Advance, the price is estimated to grow further. Considering data from situations where RACE advanced for three days, in 215 of 326 cases, the price rose further within the following month. The odds of a continued upward trend are 66%.

RACE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 25, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on RACE as a result. In 50 of 82 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 61%.

RACE moved below its 50-day moving average on September 28, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for RACE crossed bearishly below the 50-day moving average on October 01, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 18 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 56%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where RACE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 54%.

The Aroon Indicator for RACE entered a downward trend on October 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of 8 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is 23 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 54 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock slightly better than average.

The Tickeron Price Growth Rating for this company is 56 (best 1 - 100 worst), indicating steady price growth. RACE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 62 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 96 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (16.779) is normal, around the industry mean (8.703). P/E Ratio (37.704) is within average values for comparable stocks, (493.775). Projected Growth (PEG Ratio) (3.414) is also within normal values, averaging (2.450). Dividend Yield (0.011) settles around the average of (0.017) among similar stocks. P/S Ratio (8.547) is also within normal values, averaging (2.589).

Notable companies

The most notable companies in this group are Tesla (NASDAQ:TSLA), General Motors Company (NYSE:GM), Ford Motor Company (NYSE:F), NIO Inc. (NYSE:NIO).

Industry description

Automobiles continue to be arguably the most popular form of passenger travel in the U.S., and major automobile makers have revenues and market capitalizations running into multi-billions. In recent years, the industry has been experiencing some path-breaking innovations like electric vehicles and self-driving technology. While there are long-standing companies like General Motors, Ford, and Toyota Motors operating in this space, there are also emerging/rapidly growing players like Tesla – which has had a major role in the growing popularity of the electric vehicle market. With technological advancements taking steam in the auto space, we’ve also witnessed collaborations (or talks of potential partnerships) of carmakers with tech behemoths like Google’s subsidiary, Waymo.

Market Cap

The average market capitalization across the Motor Vehicles Industry is 69.67B. The market cap for tickers in the group ranges from 669 to 1.41T. TSLA holds the highest valuation in this group at 1.41T. The lowest valued company is PEVM at 669.

High and low price notable news

The average weekly price growth across all stocks in the Motor Vehicles Industry was -2%. For the same Industry, the average monthly price growth was -18%, and the average quarterly price growth was -25%. SSM experienced the highest price growth at 45%, while DCX experienced the biggest fall at -46%.

Volume

The average weekly volume growth across all stocks in the Motor Vehicles Industry was -12%. For the same stocks of the Industry, the average monthly volume growth was -19% and the average quarterly volume growth was -46%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 52
P/E Growth Rating: 60
Price Growth Rating: 74
SMR Rating: 86
Profit Risk Rating: 92
Seasonality Score: -2 (-100 ... +100)
View a ticker or compare two or three
RACE
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

an operator of an automobile company, which engages in the designing, engineering, producing and selling of sports cars

Industry MotorVehicles

Industry
Motor Vehicles
Address
Via Abetone Inferiore n. 4
Phone
+39 536949111
Employees
5718
Web
https://www.ferrari.com
Interact to see
Advertisement
UBXG stock surged +79% over the last 30 days, driven by heightened trading volume and positive market sentiment amid broader technology sector trends. Over the past quarter, the stock rose +61%, reflecting recovery from earlier lows near its 52-week bottom.
CVGI stock surged approximately +89% over the last 30 days, driven by strong Q4 2025 earnings beat on revenue and positive 2026 guidance. Over the past quarter, shares rose about +126%, reflecting improved profitability, debt reduction, and a key partnership announcement.
SAFX stock surged +104% over the past 30 days, driven by positive updates on a $10 million capital raise and merger progress. Over the past quarter, the stock rose +44%, reflecting recovery from lows amid renewable energy sector interest and strategic developments.
LONA stock surged +80% over the past 30 days, driven by positive analyst upgrades, executive appointments, and full-year financial updates highlighting pipeline progress. Over the past quarter, shares rose +48%, reflecting improved investor sentiment in biotech amid clinical advancements.
Lifetime Brands (LCUT) stock surged +77% over the last 30 days, driven by a strong Q4 earnings beat and a Zacks Rank #1 (Strong Buy) upgrade that reflects an improved earnings outlook. Over the past quarter, shares rose +48%, supported by profitability gains despite softer sales, with adjusted EBITDA reaching $50.8 million for full-year 2025.
CURV stock surged approximately +73% over the last 30 days, driven primarily by a positive reaction to Q4 and fiscal 2025 earnings that beat expectations on EPS and revenue. Over the past quarter, the stock is up around +55%, reflecting recovery from lows near $1 amid ongoing store optimization and sub-brand launches
Blaize Holdings, Inc. (BZAI) focuses on artificial intelligence (AI)-enabled edge computing solutions, offering programmable AI processors and platforms for verticals such as smart cities, defense, retail, and enterprise markets. The company's core revolves around hardware like the Graph Streaming Processor (GSP) AI accelerator, compute cards, and software tools including Blaize AI Studio—a no-code/low-code environment for deploying AI models without source code expertise. Based in El Dorado Hills, California, and founded in 2010, it went public through a merger in early 2025.
Comstock Holding Companies, Inc. (CHCI) operates as an asset manager, developer, and operator of mixed-use and transit-oriented properties, mainly in the greater Washington, D.C. metropolitan area. The company targets high-growth urban and suburban markets, overseeing a portfolio that spans residential, commercial, hospitality, and parking assets near key metro stations. Its asset-light, fee-based model delivers recurring revenue through property management, leasing, development services, and asset recapitalization for institutional investors, family offices, and governments.
ARM stock surged +26% over the past 30 days, driven by announcements of in-house chip production and strong analyst upgrades amid AI enthusiasm. Over the past quarter, the stock climbed +38%, reflecting robust Q3 earnings beat with 26% revenue growth and data center royalty doubling.
Sable Offshore Corp. (SOC) is an independent oil and gas company focused on offshore operations in federal waters off California. The company owns and operates three platforms in the Santa Ynez Unit (SYU), spanning 16 federal leases across approximately 76,000 acres, along with subsea pipelines for crude oil, natural gas, and produced water transport to onshore facilities. Its core business model centers on restarting and developing prolific fields like the SYU, which had been idle due to regulatory and legal hurdles following a 2015 pipeline spill.
From what I see, Cheniere Energy Partners (CQP) holds a commanding position through its ownership and operation of the Sabine Pass LNG terminal in Louisiana, the largest LNG production facility in the U.S. with approximately 30 million tonnes per annum (mtpa) capacity across six trains, alongside the connected Creole Trail Pipeline. This setup makes CQP a leader in U.S. LNG exports, which have accounted for about 11% of global supply in recent years. The company's ~80% contracted production through long-term sale and purchase agreements (SPAs) provides revenue stability, with weighted average remaining lives of around 13 years.
In my view, Regeneron Pharmaceuticals holds a strong leadership position in biotechnology, thanks to its proprietary VelociSuite technologies, including VelocImmune for fully human antibody discovery. This enables a robust pipeline across immunology, oncology, ophthalmology, and rare diseases. The company's integrated model—from discovery to commercialization—drives high R&D productivity, with approximately 45 clinical programs and key partnerships like Sanofi for Dupixent and Bayer for EYLEA.
As I review argenx SE's place in the market, its strong footing in immunology stands out. This commercial-stage biopharmaceutical company focuses on differentiated antibody therapies for severe autoimmune diseases. The flagship product, VYVGART (efgartigimod), a first-in-class neonatal Fc receptor (FcRn) inhibitor, has secured leadership in generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP), with approvals across the U.S., Europe, and Japan. The Immunology Innovation Program (IIP) fuels a robust pipeline, featuring next-generation FcRn candidates like ARGX-213 and ARGX-124, alongside first-in-class assets such as empasiprubart (C2 inhibitor, ARGX-117) and adimanebart (MuSK agonist).
I've long admired Alnylam Pharmaceuticals as the pioneer in RNA interference (RNAi) therapeutics, a gene-silencing technology that has delivered six approved products, including AMVUTTRA (vutrisiran), ONPATTRO (patisiran), GIVLAARI (givosiran), and OXLUMO (lumasiran). The company's proprietary platform, enhanced by GalNAc conjugation for liver targeting and emerging extra-hepatic delivery innovations, creates a solid competitive moat in precision genetic medicines.
As I review BeOne Medicines AG's position in the oncology space, what stands out is its role as a global leader with a diversified portfolio that includes both commercial-stage therapies and a deep pipeline targeting hematologic and solid tumors. The flagship product, BRUKINSA (zanubrutinib), a Bruton's Tyrosine Kinase (BTK) inhibitor, has secured approvals in over 75 markets, solidifying its dominance in chronic lymphocytic leukemia (CLL) and other blood cancers. This is complemented by TEVIMBRA (tislelizumab), an anti-PD-1 antibody approved in more than 50 markets for various indications, which broadens its reach in immunotherapy.
Rio Tinto holds a premier position as one of the world's largest mining companies, anchored by low-cost, Tier 1 assets. Its Pilbara iron ore operations in Australia deliver industry-leading margins, thanks to integrated rail and port infrastructure that gives it a structural cost advantage over higher-cost producers. In copper, the company has significant stakes in Escondida, the world's largest copper mine, and full ownership of Oyu Tolgoi in Mongolia, setting it up well to benefit from tightening supply as demand surges for electrification and renewables.
I've always been impressed by how Visa (V) commands the global payments landscape. As an open-loop network, it connects issuers, acquirers, merchants, and consumers without issuing cards or extending credit itself. The VisaNet platform processes over 65,000 transactions per second across more than 200 countries, supporting a ~52% share of the global credit card market and ~60% of debit. This scale generates powerful network effects, where greater adoption benefits everyone involved and creates formidable barriers to entry.
Following the Kenvue consumer health spin-off, Johnson & Johnson has transformed into a focused healthcare leader, emphasizing Innovative Medicine (pharmaceuticals) and MedTech (devices). In my view, this repositioning sharpens the company's edge in high-margin areas such as oncology, immunology, neuroscience, cardiovascular, surgery, and vision, where its diversified portfolio and R&D efficiency provide clear competitive advantages.
I've long appreciated ASML Holding N.V.'s dominant position in the semiconductor lithography market. The company commands over 90% share in advanced deep ultraviolet (DUV) immersion systems and 100% in EUV lithography—the critical technology for chips below 7nm nodes used in AI, high-performance computing, and memory. This near-monopoly comes from decades of R&D investment, exclusive partnerships like Zeiss for optics, and a vast installed base that generates steady service revenue. From what I see, competitors such as Nikon and Canon remain far behind in EUV, sticking to mature nodes.
I've been watching Micron Technology (MU) closely through its recent volatility, which mirrors the semiconductor sector's heightened sensitivity to AI demand and supply constraints. The stock saw a sharp post-earnings sell-off tied to elevated capital expenditure plans, yet it has rebounded with surging DRAM prices—up 90-95%—and memory suppliers booked out for years. From what I see, broader tech optimism, including key partnerships and persistent supply tightness, is driving upward momentum. This positions MU as a pivotal player in high-bandwidth memory (HBM) for data centers. Trading near recent highs around $368, the shares highlight investor focus on Micron's critical role in the AI infrastructure expansion under these constrained industry conditions.
Ferrari (RACE) Shares Climb +8% on Strong Q2 Earnings and Raised Guidance